Research Peptides — 6-Panel Analytical Testing, Every Lot

Snapshot CJC-1295 No DAC (GHRH analog) and ipamorelin (GHS-R1a agonist) stimulate endogenous GH through complementary cAMP and Ca²⁺ signaling pathways. Clinical and mechanistic studies of GHRH+GHS-R1a agonists co-administration demonstrate amplified pulsatile GH release compared to either pathway alone, supporting dual-axis activation of the somatotroph system. What Is CJC-1295 Without DAC? CJC-1295 without DAC is a synthetic analog of growth hormone–releasing hormone (GHRH amino acid 1–29 or Mod GHF1-29 ). This CJC-1295 is designed to stimulate endogenous growth hormone (GH) secretion through activation of the GHRH receptor (GHRH-R) on anterior pituitary somatotrophs. Without the Drug Affinity Complex (DAC), it does not bind albumin, resulting in a shorter half-life and more physiologic, pulse-like GH stimulation. Mechanistically, it activates the adenylyl cyclase–cAMP–protein kinase A (PKA) signaling cascade, promoting GH release and downstream increases in circulating insulin-like growth factor-1 (IGF-1) [1]. Because it works upstream at the hypothalamic–pituitary axis, CJC-1295 without DAC preserves endogenous inhibitory feedback regulation via somatostatin and IGF-1. What Is Ipamorelin? Ipamorelin is a selective growth hormone secretagogue (GHS) that binds to the ghrelin receptor (GHS-R1a) on anterior pituitary somatotrophs [2]. It stimulates endogenous GH release primarily through activation of the phospholipase C (PLC)–IP3–calcium signaling pathway, increasing intracellular calcium and promoting pulsatile GH secretion [3]. Unlike earlier GHS compounds and ghrelin itself, ipamorelin is relatively selective for GH release, with minimal stimulation of ACTH, cortisol, or hunger compared to less selective secretagogues [2]. By acting through a pathway distinct from GHRH analogs, ipamorelin is frequently studied in combination paradigms evaluating complementary stimulation of the somatotroph axis. Synergy CJC-1295 without DAC and ipamorelin stimulate endogenous growth hormone (GH) release through distinct but convergent regulatory pathways within the HPA axis. Their combined use is based on dual activation of GHRH and ghrelin receptor systems via: GHRH receptor > adenylyl cyclase–cAMP–PKA (CJC-1295) GHS-R1a > phospholipase C (PLC)–IP3–Ca²⁺(Ipamorelin) Because these pathways operate independently, their combined activation should increase both the magnitude and efficiency of GH pulsatility. Although published studies typically evaluate GHRH combined with GHRP compounds (such as GHRP-6 or ghrelin) rather than ipamorelin specifically, the mechanistic framework likely applies to ipamorelin due to its selective GHS-R1a agonism. Cell-based studies demonstrate that co-activation of GHRH and GHS receptors can produce approximately twofold greater cAMP signaling compared to GHRH alone, suggesting receptor-level cross-talk and amplification of somatotroph responsiveness [4]. A clinical study evaluated whether ghrelin, the endogenous ligand for the GHS receptor, interacts synergistically with growth hormone–releasing hormone (GHRH) to stimulate GH secretion [5]. 8 male adults were administered ghrelin (0.08, 0.2, and 1.0 μg/kg) intravenously alone or combined with 1.0 μg/kg GHRH. Results showed that combined administration with GHRH: Produced significantly greater GH responses than either peptide alone (p < 0.05)[a] GH response exceeded the sum of the individual responses, demonstrating true supra-additive synergy (p < 0.050 No synergistic interaction with ACTH or prolactin secretion This study demonstrates that co-administration of ghrelin and GHRH produces true synergistic GH release in humans, exceeding additive stimulation from either agent alone. The findings support the concept that dual activation of the GHRH receptor and GHS receptor enhances pituitary somatotroph responsiveness. In some metabolic conditions (e.g., obesity-associated blunting of GHRH response), GHS agonists partially restored GH responsiveness [6]. Ipamorelin Pairing Ipamorelin is highlighted in research contexts due to its relative selectivity for GH release, with minimal stimulation of ACTH and cortisol compared to earlier GHRP compounds. This selective profile may allow more targeted evaluation of somatotroph activation without broader pituitary axis activation. When paired with a short-acting GHRH analog such as CJC-1295 without DAC, the goal is typically to: Preserve physiologic pulsatility Enhance GH pulse amplitude Maintain endogenous feedback regulation The absence of the DAC component in CJC-1295 results in a shorter half-life, aligning more closely with natural episodic GH dynamics rather than prolonged elevation. Dose and Ratio Considerations Balanced ratios such as 2 mg + 2 mg or 5 mg + 5 mg can be conceptually described as targeting simultaneous engagement of: The GHRH-R/cAMP axis (transcriptional and secretory priming) The GHS-R1a/Ca²⁺ axis (secretory amplification) Proportional dosing may theoretically promote coordinated receptor activation. However, precise optimization of dose ratios has not been definitively established in controlled combination trials and remains an empirical parameter in research settings. References: 1 Sackmann-Sala, L., Ding, J., Frohman, L. A. and Kopchick, J. J. (2009) Activation of the GH/IGF-1 axis by CJC-1295, a long-acting GHRH analog, results in serum protein profile changes in normal adult subjects. Growth Horm. IGF Res., Elsevier BV 19, 471–477 2 Raun, K., Hansen, B. S., Johansen, N. L., Thøgersen, H., Madsen, K., Ankersen, M., et al. (1998) Ipamorelin, the first selective growth hormone secretagogue. Eur. J. Endocrinol., Oxford University Press (OUP) 139, 552–561 3 Mear, Y., Enjalbert, A. and Thirion, S. (2013) GHS-R1a constitutive activity and its physiological relevance. Front. Neurosci., Frontiers Media SA 7, 87 4 Cunha, S. R. and Mayo, K. E. (2002) Ghrelin and growth hormone (GH) secretagogues potentiate GH-releasing hormone (GHRH)-induced cyclic adenosine 3’,5'-monophosphate production in cells expressing transfected GHRH and GH secretagogue receptors. Endocrinology, The Endocrine Society 143, 4570–4582 5 Hataya, Y., Akamizu, T., Takaya, K., Kanamoto, N., Ariyasu, H., Saijo, M., et al. (2001) A low dose of ghrelin stimulates growth hormone (GH) release synergistically with GH-releasing hormone in humans. J. Clin. Endocrinol. Metab., The Endocrine Society 86, 4552 6 Popovic, V., Damjanovic, S., Micic, D., Djurovic, M., Dieguez, C. and Casanueva, F. F. (1995) Blocked growth hormone-releasing peptide (GHRP-6)-induced GH secretion and absence of the synergic action of GHRP-6 plus GH-releasing hormone in patients with hypothalamopituitary disconnection: evidence that GHRP-6 main action is exerted at the hypothalamic level. J. Clin. Endocrinol. Metab., The Endocrine Society 80, 942–947 [a]As currently written, only this first bullet point grammatically fits the intro sentence. "Combined administration" is functioning as the subject, and "produced" is the verb. The other two don't begin with similar verbs (and have different structures). Needs to be harmonized, and there are multiple ways you could do that, making sure that each bullet matches the intro. Also: There is an issue in that the bullets indicate 3 variations: ghrelin alone, GHRH alone, and both combined. But the description above only says "ghrelin alone or combined with GHRH." That's only 2 variations. There is no GHRH alone mentioned above.

What is MOTS-c peptide? MOTS-c is a mitochondrial-derived and exercise-induced peptide whose levels decrease with age [1]. It improves insulin sensitivity, glucose metabolism, and metabolic homeostasis [2]. Animal studies suggest that, by activating AMPK, it can mitigate obesity resulting from high-fat diets, aging, and menopause [3, 2]. It also regulates age-related inflammation and various aspects of age-related physical decline, such as bone and muscle losses [1]. MOTS-c peptide benefits and side effects Metabolic and cardiovascular health In pancreatic cells, MOTS-c lowers insulin secretion and increases glucagon production [4]. In mice with aberrant lipid metabolism, MOTS-c treatment significantly reduced lipid buildup in liver cells [5]. In rodents, high-fat diet-induced obesity can promote insulin resistance and fat accumulation that triggers chronic inflammation. In mice, MOTS-c administration protects against both age-related and high-fat diet-induced insulin resistance, and diet-induced obesity [6]. Hormonal changes during pregnancy can affect insulin sensitivity and cause high blood sugar, leading to gestational diabetes. In pregnant women and mouse models of gestational diabetes, MOTS-c normalized blood sugar, and enhanced insulin sensitivity and glucose tolerance. The MOTS-c treatment lowered both the birth weight-associated complications and mortality of offspring caused by gestational diabetes [7]. Low estrogen during menopause can cause weight gain and fat redistribution in favor of white fats, which increases insulin resistance and the risk of metabolic disorders. In contrast, the more mitochondria-dense brown fats burn more calories, and improve glucose and lipid metabolisms. In ovarectomized mice, MOTS-c increases brown fat activation, and reduces fat accumulation and inflammation in white adipose tissue, which contributes to the lower level of fats in serum and liver [3]. In heart failure, fluid buildup and increased pressure in the lungs can cause lung injury. MOTS-c reduced heart dysfunction and remodeling caused by heart failure and lowered inflammation while boosting antioxidant activity in the hearts of sick mice [8]. It can also prolong injured heart and lung cells’ life cycle [9, 10]. Muscle building and bone health Age-related sarcopenia can reduce overall healthspan and independence, while increasing various metabolic health risks. MOTS-c suppresses myostatin and lipid infiltration that contributes to muscle atrophy, even in immobilized animals [11, 12]. Older adults with higher circulating MOTS-c have better muscle performance and lean mass, while those with lower levels experienced more sarcopenia [13]. In a mouse model of aging, MOTS-c can significantly increase physical performance by activating genes related to skeletal muscle metabolism and myoblast adaptation to metabolic stress [1]. In an in vitro model of muscle development, MOTS-c peptide helps muscle cells to form properly, affecting their integral parts such as myotubes. It supports muscle cell formation at the expense of lipid accumulation while protecting muscle cells from the breakdown effects of inflammatory cytokine IL-6 [14]. Age-related bone loss often parallels muscle loss, and various anti-sacropenic stimuli also protect bone health. Importantly, metabolic dysfunction and inflammation tend to accelerate bone loss. MOTS-c mitigates age-related bone loss by stimulating osteoblasts and suppressing osteoclasts by modulating AMPK and inflammatory responses [15]. In a mouse bone damage model, MOTS-c treatment reduced bone loss and inflammation and prevented the formation of osteoclasts [16]. Anti-inflammatory and antioxidant benefits Sepsis is a potentially lethal condition characterized by systemic overactive immune reactions towards an infection or noninfectious agents. MOTS-c greatly improves survival and lowers bacterial counts in MRSA-infected experimental mice. It also reduces levels of pro-inflammatory cytokines like TNF-α, IL-6, and IL-1β, while increasing the anti-inflammatory cytokine IL-10 [17]. Type 1 diabetes patients have lower endogenous MOTS-c levels than healthy controls. In a mouse model of type 1 diabetes, exogenous MOTS-c prevents pancreatic β cell destruction by shifting CD4+ T cells towards a less self-destructive phenotype, suggesting that MOTS-c may be beneficial as an autoimmune treatment [18]. Age-related inflammation and declining antioxidant capacity are key drivers of aging and related diseases. Older adults aged 70–81 years have 20% less MOTS-c than younger adults 18–30 years old [19]. In a mouse model of type 2 diabetes, MOTS-c administration increased antioxidant enzymes like SOD and CAT, protecting myocardial cells from oxidative stress [20]. Neuropathic pain Unlike acute pain, neuropathic pain is pain caused by nervous system dysfunction related to nerve damages, rather than by injury or inflammation. MOTS-c’s antinociceptive effects pertain to its ability to restore mitochondrial health, and inhibit microglial and pain signals in the spinal cord [21]. Furthermore, compared to morphine, MOTS-c has far fewer side effects such as gastrointestinal transit inhibition and motor incoordination [22].

What is epitalon peptide? Epitalon, also known as Epithalone or Epithalon, is a synthetic tetrapeptide (Ala–Glu–Asp–Gly) derived from a naturally occurring pineal gland extract (epithalamin) [1]. Structurally, epitalon mimics endogenous peptides that influence the activity of telomerase, the enzyme responsible for maintaining telomere length. Epitalon may also modulate oxidative stress regulation, circadian rhythm stabilization, and neuroendocrine function. Epitalon peptide benefits Anti-aging and longevity One of the most widely studied aspects of epitalon is its potential influence on cellular aging through multiple biochemical pathways. A cell study investigated whether Epithalon can influence two processes central to dementia, cholinesterase activity and the formation of the soluble form of amyloid precursor protein (sAPP) in human neuroblastoma (SH-SY5Y) cells [2]. Results showed that Epithalon: Reduced excessive cholinesterase enzymatic activity. Increased sAPP formation, which is protective against Alzheimer’s-type pathology. These effects suggest that epitalon may delay or prevent mechanisms underlying conditions like Alzheimer’s disease. Similar anti-aging effects are also seen in other tissues, such as in the prevention of age-based pigmentary retinal dystrophy in genetically predisposed rats [3]. Antioxidant Oxidative stress is a central contributor to cellular aging and carcinogenesis, as unmanaged oxidative species can damage lipids, proteins, and DNA. Epitalon can mitigate such damages by enhancing endogenous antioxidant defenses. In a fruit fly study, synthetic Epithalon’s antioxidant activities were compared with the crude pineal extract, epithalamin [4]. Epitalon was added to larval nutrient medium at 0.00001 wt%, while epithalamin was added at concentrations 1000-fold higher. Epitalon addition resulted in: 20% Increased catalase activity (p<0.05) 20-50% decreased CHP content (marker of lipid peroxidation) (p<0.05) ~1000-fold higher biological activity than epithalamin Anticarcinogenic A study evaluated the effect of epitalon on tumor development and oncogene expression in 80 transgenic HER-2/neu mice, a model predisposed to breast cancer and accelerated aging [5]. Mice were either given saline as negative control, Vilon as a positive control, or Epithalon (1 µg, subcutaneous) for 5 consecutive days monthly. Results showed that epitalon: Delayed first tumor appearance by 38 days compared to Vilon, and by 20 days compared to saline. Reduced recurring tumor incidence: 28% remained tumor-free vs.18% (saline). Lowered tumor multiplicity: only 56% had ≥2 tumors vs. 75% (saline). Reduced maximum tumor diameter by 33% (p<0.05).  3.7-fold lower HER-2/neu mRNA expression compared to saline (p<0.001), whereas Vilon produced a 1.97-fold lower HER-2/neu expression. Telomere protection A defining feature of epitalon is its reported influence on telomerase activity. Telomerase is the ribonucleoprotein enzyme responsible for elongating telomeric DNA, maintaining chromosomal stability. In most somatic cells, telomerase activity is repressed, which leads to progressive telomere shortening during replication. When telomeres become critically short, cells enter senescence, a hallmark of aging [6]. An in vitro study evaluated whether epitalon can activate telomerase and elongate telomeres in human somatic cells [7]. Human fetal fibroblasts were exposed to epitalon at varying concentrations, resulting in: Increased telomerase Telomere elongation Extended proliferative capacity beyond the normal Hayflick limit (40-60 replications before senescence and death) Circadian rhythm Epitalon has been linked to pineal gland regulation through melatonin, a hormone that regulates sleep–wake cycles and seasonal biological rhythms. Melatonin naturally declines with age. An animal study evaluated whether epitalon can restore melatonin secretion and normalize circadian rhythms of cortisol production in aged female rhesus monkeys [8]. The experimental group received 10 µg of epitalon intramuscularly, once daily for 10 days, while the control group received saline. epitalon administration resulted in: A three-fold increase in evening melatonin secretion (48 vs. 15 pg/ml, p < 0.001) Restoration of normal day-night variations of circadian cortisol rhythm Effects selective for aged animals only Metabolic regulation Age-related changes in mitochondria, nutrient sensing, and hormone signaling may underpin metabolic changes that result in insulin resistance and other related diseases. Epitalon works partly by addressing these mechanisms, according to a study in rhesus monkeys [9]. Seven young (6–8 years) and seven old (20–27 years) monkeys were administered epitalon intramuscularly (10 µg/day for 10 days). After administration, older monkeys had: Decreased basal glucose concentration Improved glucose clearance rate (p<0.01) Restored early-phase insulin secretion (320% vs. 198% control, p<0.05) Improved late-phase insulin dynamics Glucose tolerance improvements persisted for 1–2 months post-treatment, even after epitalon withdrawal.